Candidiasis Drugs Market Size

Candidiasis Drugs Market size was over USD 822.3 million in 2023 and is anticipated to reach USD 1.77 billion by 2036, witnessing around 6.1% CAGR during the forecast period i.e., between 2024-2036. In the year 2024, the industry size of candidiasis drugs is estimated at USD 862.43 million. Candida is a yeast, that causes infection in the mucosal layer. The growth of the market can be attributed to the growing cases of yeast infection across the world, backed by poor immunity, sanitation practices, and others. The increasing health awareness, availability of anti-fungal drugs, and growing investment in development of new drugs, is estimated to boost the market growth. Candida is usually present inside the skin, in parts lined with mucous, such as the mouth, throat, gut, and vagina, without causing any problems. Infections are caused when the yeast grows out of control, due to high amount of sugar in blood, high humidity, or poor hygiene. Diabetes is a major factor for candidiasis infection, as raised blood sugar promotes yeast activation. The growing incidences of diabetes is estimated to boost the market growth over the forecast period. According to the report by the World Health Organization (WHO), 422 million people worldwide suffer from diabetes, in countries of all income levels, and around 1.6 million deaths are directly attributed to it each year.